30 closest matches · ranked by relevance
Carcinoma, Squamous Cell of Head and Neck · Oropharynx Squamous Cell Carcinoma
Primary: One-year Progression-free Survival (PFS) — 97.50 percentage of participants
Squamous Cell Carcinoma of Oropharynx
Primary: Percentage of Patients Free of Grade 3+ Late Toxicity — 86 percentage of participants
Oral Squamous Cell Carcinoma
Primary: Pathologic Response. — 25; 2; 4; 4 Participants
Carcinoma, Squamous Cell · Head and Neck Neoplasms · Oropharyngeal Neoplasms
Primary: 2 Year Progression Free Survival After De-intensified Chemoradiotherapy (CRT) in Human Papilloma Virus (HPV)-Positive and/or p16 Positive Low-risk Oropharyngeal Squamous…
Oropharynx Squamous Cell Carcinoma
Primary: Progression-free Survival (PFS) — 65 percentage of patients
Oropharyngeal Cancer
Primary: Percentage of Participants With Local Control — 97.9 percentage of patients
Squamous Cell Carcinoma of the Oropharynx · HPV
Primary: Rate of Recurrence — 8 Participants
Oropharyngeal Squamous Cell Cancer
Primary: Median Change in Quality of Life (QOL) From Baseline to 12 Months Post Treatment — -4.2; 0; 6.3; 10.7 score on a scale
Human Papilloma Virus · Oropharyngeal Squamous Cell Carcinoma
Primary: Disease Specific Survival (DSS) — 29; 15; 15 participants
Oropharynx Cancer
Primary: Grade 3+ Adverse Events Rate — .032; .115 events per participant
Head and Neck Cancer · Precancerous Condition
Primary: Overall Survival — 84.6; 77.9 percentage of participants
Carcinoma, Squamous Cell · Head and Neck Neoplasms · Oropharyngeal Neoplasms
Primary: Pathologic Complete Response Rate After De-escalated CRT in HPV-positive and/or p16 Positive Oropharyngeal Squamous Cell Carcinoma (OPSCC). — 37 Participants
Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck
Primary: Objective Response Rate (ORR) — 16.2; 14.6; 18.9; 10.0 % of participants
Head and Neck Cancer
Primary: Clinical and Radiological Complete Clinical Response (crCR) Rate at 3 Months — 9; 8; 4 participants
Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Overall Response Rate — 37 Participants
HPV-Related Squamous Cell Carcinoma · HNSCC
Primary: Evaluate the Tumor Shrinkage (%) to Measure the Deep Response Rate (DRR) — 25; 26; 0 Participants
Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Median Overall Survival — 231 Days
Oropharynx Cancer
Primary: The Percentage of Patients With Local Regional Recurrence (LRR) of Disease — 2; 3 percentage of participants
Human Papillomavirus Infection · Stage I Oropharyngeal Squamous Cell Carcinoma · Stage II Oropharyngeal Squamous Cell Carcinoma
Primary: 2-year Loco-regional Tumor Control (LRC) Rate — 100; 93; 96.2 percentage of patients
Head and Neck Cancer · Precancerous Condition
Primary: 24-month Progression-free Survival — 64 percentage of participants
Cancer
Primary: Toxicities Associated With Combined Radiotherapy and Erlotinib Treatments. — 15; 14; 12; 13 number of adverse events
Head and Neck Cancer
Primary: 1-year Local Control — NA; NA months
Human Papilloma Virus Infection · Stage III Squamous Cell Carcinoma of the Oropharynx · Stage IVA Squamous Cell Carcinoma of the Oropharynx
Primary: Progression-Free Survival (PFS), Evaluated Using RECIST Version (v) 1.1 — 94.5 percentage of participants
Head and Neck Carcinoma
Primary: Overall Response Rate — 22.7 percentage
Squamous Cell Carcinoma of the Head and Neck
Primary: Maximum Tolerated Dose (MTD) of Olaparib — 50 mg twice daily
Human Papillomavirus-Related Carcinoma · Oropharyngeal Cancer
Primary: Maximally Tolerated Dose/Fractionation of Hypofractionated Radiation Therapy — 0 Participants
Recurrent Oropharynx Carcinoma
Primary: Patient Reported Swallowing Related Quality of Life — 50; 40; 40 score on a scale
Recurrent Head and Neck Cancer
Primary: Disease-free Survival at 2 Years — 111 Participants
Head and Neck Neoplasms
Primary: Percentage of Participants With Objective Response (OR) of Complete Response (CR) or Partial Response (PR) — 12.5 Percentage of participants
Head and Neck Squamous Cell Carcinoma
Primary: Change in Immune Response After Tadalafil Administration